318 related articles for article (PubMed ID: 35168870)
41. Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation.
Roder L; Simonsen M; Fitzpatrick L; He J; Loucks J
J Manag Care Spec Pharm; 2022 Sep; 28(9):989-996. PubMed ID: 36001103
[No Abstract] [Full Text] [Related]
42. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers.
Bijvelds MJC; Roos FJM; Meijsen KF; Roest HP; Verstegen MMA; Janssens HM; van der Laan LJW; de Jonge HR
J Cyst Fibros; 2022 May; 21(3):537-543. PubMed ID: 34922851
[TBL] [Abstract][Full Text] [Related]
43. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C
J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431
[TBL] [Abstract][Full Text] [Related]
44. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
45. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
46. Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients' Plasma by a Novel LC-MS/MS Method.
Pigliasco F; Cafaro A; Stella M; Baiardi G; Barco S; Pedemonte N; D'Orsi C; Cresta F; Casciaro R; Castellani C; Calevo MG; Mattioli F; Cangemi G
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831163
[TBL] [Abstract][Full Text] [Related]
47. Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis.
Gushue C; Eisner M; Bai S; Johnson T; Holtzlander M; McCoy K; Sheikh S
Pediatr Pulmonol; 2023 Aug; 58(8):2308-2316. PubMed ID: 37222417
[TBL] [Abstract][Full Text] [Related]
48. Tezacaftor and ivacaftor for the treatment of cystic fibrosis.
Paterson SL; Barry PJ; Horsley AR
Expert Rev Respir Med; 2020 Jan; 14(1):15-30. PubMed ID: 31626570
[No Abstract] [Full Text] [Related]
49. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
50. Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease.
Giallongo A; Parisi GF; Papale M; Manti S; Mulé E; Aloisio D; Terlizzi V; Rotolo N; Leonardi S
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833376
[TBL] [Abstract][Full Text] [Related]
51. A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatment.
Bhaskaran D; Bateman K
J Cyst Fibros; 2022 Nov; 21(6):1077-1079. PubMed ID: 35840534
[TBL] [Abstract][Full Text] [Related]
52. Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus.
Patyna S; Büttner S; Eckes T; Obermüller N; Bartel C; Braner A; Trautmann S; Thomas D; Geiger H; Pfeilschifter J; Koch A
Prostaglandins Other Lipid Mediat; 2019 Oct; 144():106348. PubMed ID: 31301404
[TBL] [Abstract][Full Text] [Related]
53. Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study.
Milo F; Ciciriello F; Alghisi F; Tabarini P
J Cyst Fibros; 2023 May; 22(3):414-419. PubMed ID: 36549989
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.
Kapouni N; Moustaki M; Douros K; Loukou I
Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980112
[TBL] [Abstract][Full Text] [Related]
55. A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation.
Knott-Torcal C; Sebastián-Valles F; Girón Moreno RM; Martín-Adán JC; Jiménez-Díaz J; Marazuela M; Sánchez de la Blanca N; Fernández-Contreras R; Arranz-Martín A
Clin Nutr; 2023 Dec; 42(12):2468-2474. PubMed ID: 38411018
[TBL] [Abstract][Full Text] [Related]
56. Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials.
Keogh RH; Cosgriff R; Andrinopoulou ER; Brownlee KG; Carr SB; Diaz-Ordaz K; Granger E; Jewell NP; Lewin A; Leyrat C; Schlüter DK; van Smeden M; Szczesniak RD; Connett GJ
Thorax; 2022 Sep; 77(9):873-881. PubMed ID: 34556554
[TBL] [Abstract][Full Text] [Related]
57. Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome.
Marsh R; Dos Santos C; Hanson L; Ng C; Major G; Smyth AR; Rivett D; van der Gast C
Microbiol Spectr; 2023 Aug; 11(5):e0117523. PubMed ID: 37607068
[TBL] [Abstract][Full Text] [Related]
58. Use of CFTR modulators in special populations, part 3: Solid organ transplant.
Kadouh NK; Elijah J; Fitzgerald LJ; Phan H
Pediatr Pulmonol; 2023 Dec; 58(12):3393-3402. PubMed ID: 37067449
[TBL] [Abstract][Full Text] [Related]
59. Real-world data on the efficacy and safety of tezacaftor-ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation.
Vincken S; Verbanck S; Braun S; Buyck N; Knoop C; Vanderhelst E
Acta Clin Belg; 2023 Aug; 78(4):280-284. PubMed ID: 36415912
[TBL] [Abstract][Full Text] [Related]
60. The combination elexacaftor/tezacaftor/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner.
Liessi N; Tomati V; Capurro V; Loberto N; Garcia-Aloy M; Franceschi P; Aureli M; Pedemonte N; Armirotti A
J Cyst Fibros; 2023 Jul; 22(4):680-682. PubMed ID: 37088636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
